Primary Treatment for Metastatic Basal Cell Cancer

First-Line Treatment Options

The American Academy of Dermatology recommends the primary treatment for metastatic basal cell carcinoma (BCC) is systemic therapy with a hedgehog pathway inhibitor, specifically FDA-approved medications vismodegib or sonidegib, managed by a multidisciplinary tumor board 1, 2
The National Comprehensive Cancer Network recommends that whenever possible, nodal or distant metastases should first be evaluated for potential surgical resection with or without radiation therapy 3, 4
For patients with distant metastases, multidisciplinary consultation is recommended to guide treatment with hedgehog pathway inhibitors 1, 2

Vismodegib demonstrated an objective response rate of 30-33% in metastatic BCC patients, with a median duration of response of 7.6 months, according to the American Academy of Dermatology 1, 5
The majority of patients (73%) experienced tumor shrinkage with vismodegib, though all responses were partial rather than complete, as reported by the American Academy of Dermatology 1
The STEVIE trial showed an overall response rate of 37.9% with vismodegib in metastatic BCC, according to the American Academy of Dermatology 1, 5

If hedgehog pathway inhibitors are not feasible or fail, platinum-based chemotherapy may be considered, as recommended by the American Academy of Dermatology 1, 2
Best supportive and palliative care should be provided to optimize symptom management and maximize quality of life, according to the American Academy of Dermatology 1, 2

Hedgehog pathway inhibitors are associated with significant adverse events, including common side effects such as muscle spasms, arthralgias, alopecia, dysgeusia, and weight loss, as reported by the American Academy of Dermatology 1, 5
In the STEVIE trial, 36% of patients discontinued treatment due to adverse events, according to the American Academy of Dermatology 1

Close follow-up is essential as 30-50% of BCC patients develop another BCC within 5 years, as recommended by the National Comprehensive Cancer Network 3, 4
Complete skin examinations should occur at least every 6-12 months during the first 2 years after treatment, according to the National Comprehensive Cancer Network 3, 4
Patients should be educated about sun protection and regular self-examination of the skin, as recommended by the National Comprehensive Cancer Network 3

Other hedgehog pathway inhibitors (itraconazole, saridegib) have shown responses in small studies but not in patients previously treated with vismodegib, according to the National Comprehensive Cancer Network 4